• Q4 Revenue Surge: Vericel Corp (NASDAQ:VCEL) reported a 23% increase in Q4 revenue, reaching $65.0 million.

• Full-Year Revenue Growth: Full-year 2023 revenue grew by 20% to $197.5 million.

• Net Income Leap: Q4 net income soared by 119% to $13.0 million, or $0.26 per diluted share.

• Adjusted EBITDA Growth: Adjusted EBITDA for Q4 increased by 50% to $22.3 million, with a margin of 34%.

• 2024 Financial Guidance: Vericel anticipates 2024 total net revenue to be between $237 to $241 million with an adjusted EBITDA margin of approximately 20%.

• Warning! GuruFocus has detected 4 Warning Sign with VCEL.

On February 29, 2024, Vericel Corp (NASDAQ:VCEL) released its 8-K filing, detailing a strong financial performance for the fourth quarter and full year of 2023. The company, a fully integrated, commercial-stage biopharmaceutical company specializing in advanced therapies for sports medicine and severe burn care markets, has reported significant growth in both revenue and profitability metrics.

Financial Performance and Highlights

Vericel's total net revenue for Q4 2023 increased by 23% to $65.0 million, compared to the same period in the previous year. This growth was driven by a 22% increase in MACI net revenue, which reached $56.7 million, and a 31% increase in Burn Care net revenue, totaling $8.3 million. The company's gross margin for the quarter stood at an impressive 75%, contributing to a net income growth of 119% to $13.0 million, or $0.26 per diluted share. The non-GAAP adjusted EBITDA also saw a significant increase of 50% to $22.3 million, representing an adjusted EBITDA margin of 34%.

For the full year of 2023, Vericel achieved a 20% increase in total net revenue, amounting to $197.5 million. The MACI net revenue saw a 25% growth, reaching $164.8 million, while Burn Care net revenue was reported at $32.7 million. The company maintained a strong gross margin of 69% for the year, despite reporting a net loss of $3.2 million, or $0.07 per diluted share. However, the non-GAAP adjusted EBITDA for the year was positive at $33.9 million, with a margin of 17%.

Operational Achievements and Future Outlook

Vericel's operational achievements in Q4 included the highest number of MACI implants, implanting surgeons, surgeons taking biopsies, and MACI biopsies since the product's launch. The company also reported the highest number of Epicel biopsies in a quarter since 2021. Looking ahead, Vericel provided a positive outlook for 2024, with total net revenue expected to be in the range of $237 to $241 million and an anticipated gross margin of approximately 70%. The adjusted EBITDA margin is projected to be around 20%.